AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00590538
Drug: Genistein (Unconjugated Isoflavones 100)
DrugBank: Genistein (DB01645)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every participant will be administered a perfusion of 50 MicroM of Genistein (Unconjugated Isoflavones 100) during the modified NPD procedure.
Trial: NCT01118572
Drug: YM177
RxNorm normalized name: Tezepelumab
DrugBank: Tezepelumab (DB15090)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03943823
Drug: Estrogen vaginal cream
RxNorm normalized name: estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Either Premarin or Estrace cream will be used (dependent on patient's insurance). Premarin 1 gram every night for the first 7 days, then 0.5 grams twice weekly. Estrace cream 2 grams daily for first 7 days, then 1 gram twice-weekly.
Trial: NCT01303614
Drug: Lidocaine-Prilocaine cream
RxNorm normalized name: lidocaine / prilocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implementation of 3 cm of lidocaine-prilocaine in the endocervical canal, 10 minutes before the intervention with a syringe without needle 5ml. Application, with a swab of the anesthetic cream ectocervix level.
Trial: NCT00703118
Drug: Telaprevir
RxNorm normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive telaprevir tablets of 750 mg orally eight hourly for 12 weeks in group A and B.
Trial: NCT00703118
Drug: Peg-IFN-alfa-2a
RxNorm normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive 180 µg subcutaneous (under the skin) injection of Peg-IFN-alfa-2a once weekly for 48 weeks in Group A, B and C.
Trial: NCT00703118
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive ribavirin tablets of 1000-1200 mg orally twice daily for 48 weeks in Group A, B, and C.
Trial: NCT01785758
Drug: Sugammadex (4 mg/Kg)
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sugammadex administered at the end of surgical procedure, once skin suture had been finished, to reverse profound neuromuscular blockade induced and maintained with rocuronium
Trial: NCT03120494
Drug: Emtricitabine and Tenofovir
RxNorm normalized name: emtricitabine and tenofovir alafenamide
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All subjects will be provided study drug for use daily for one year.
Trial: NCT04046822
Drug: Liraglutide 6 MG/ML [Saxenda]
RxNorm normalized name: liraglutide 6 MG/ML [Saxenda]
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liraglutide is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the liraglutide dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
Trial: NCT00001341
Drug: ZD1694 (TOMUDEX)
RxNorm normalized name: Tomudex
DrugBank: Raltitrexed (DB00293)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01129375
Drug: omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: delayed-release capsule~Route of administration:oral
Trial: NCT02697734
Drug: osilodrostat
RxNorm normalized name: osilodrostat
DrugBank: Osilodrostat (DB11837)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In the form of filmcoated tablets for oral administration, in the following dose strengths: 1 mg, 5 mg, 10 mg, and 20 mg.
Trial: NCT02697734
Drug: osilodrostat Placebo
RxNorm normalized name: osilodrostat
DrugBank: Osilodrostat (DB11837)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Matching Placebo in the form of filmcoated tablets for oral administration
Trial: NCT00243568
Drug: Vicriviroc
RxNorm normalized name: Vicriviroc
DrugBank: Vicriviroc (DB06652)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01315795
Drug: Lanreotide Autogel 90 mg and 120 mg
RxNorm normalized name: lanreotide
DrugBank: Lanreotide (DB06791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: administration of lanreotide sc every 4 weeks (28 days)
Trial: NCT01276912
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine therapy with a dosage adjusted to get FBG ≤ 5.3mmol / L as the goal, accompanied with a lifestyle counseling.
Trial: NCT02452255
Drug: Fenofibrate
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fenofibrate by mouth given daily throughout hospitalization for up to 12 months
Trial: NCT02452255
Drug: Propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol by mouth given daily throughout hospitalization for up to 12 months
Trial: NCT00002823
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002823
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002823
Drug: vinblastine sulfate
RxNorm normalized name: Vinblastine Sulfate
DrugBank: Vinblastine (DB00570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002823
Drug: vindesine
RxNorm normalized name: vindesine
DrugBank: Vindesine (DB00309)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002823
Drug: vinorelbine tartrate
RxNorm normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00814541
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00814541
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01497548
Drug: Methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate started at 5mg on morning (0800) and noon (1200) on day 1. Dose increased to 10mg on morning (0800) and noon (1200) on day 3; 15mg on morning and noon on day 6 depending on the clinical response. Similarly, the dose can be reduced to 5mg/day if patients are not able to tolerate a higher dose. The treatment continues until day 28.
Trial: NCT05765357
Drug: Trastuzumab for injection
RxNorm normalized name: trastuzumab Injection
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab for injection manufactured by Chia Tai Tianqing. Trastuzumab is a humanized IGG1-class monoclonal antibody produced by CHO cells. Its mechanism of action is to prevent the attachment of human epidermal growth factor to Her2 by attaching itself to Her2, thus blocking the growth of cancer cells. In addition, Trastuzumab can also stimulate the body's own immune cells to destroy cancer cells.
Trial: NCT04933864
Drug: Methylene Blue and Photodynamic Therapy
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group. Methylene blue (SamaraMedProm, Russia, Registration number: MP-001834, 13.09.2012) 1 mg/kg concentration orally one time were added to the current therapy of the participant (e.g., azithromycin, hydroxychloroquine, aminodihydrophthalazinedione sodium, levofloxacin, etc.), if any, and irradiation of the participant's chest was performed by 650 nm laser source (UFPh-675-01-BIOSPEC, BIOSPEC, Russia, Registration number: 2009/04648, 26.03.2009) with 18 J/cm\^2 energy dose.~For critically ill participants: Inhalation by 0.2 mg methylene blue (SamaraMedProm, Russia, Registration number: MP-001834, 13.09.2012) 10 ml water solution and irradiation of pharynx and nasal cavity by 650 nm laser source (UFPh-675-01-BIOSPEC, BIOSPEC, Russia, Registration number: 2009/04648, 26.03.2009) with 36 J/cm\^2 energy dose were performed.
Trial: NCT00191802
Drug: teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02801370
Drug: 12 mg ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single administration of OTO-201
Trial: NCT02801370
Drug: Sham Control
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
DrugBank: Bean (DB14709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simulated, single adminstration
Trial: NCT03013985
Drug: Glargine U300
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Glargine U300 is a new generation long-acting insulin.
Trial: NCT03013985
Drug: Glargine U100
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Glargine U100 is a long-acting insulin.
Trial: NCT00076869
Drug: MK0991, caspofungin acetate
DrugBank: Caspofungin (DB00520)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00076869
Drug: Comparator: amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00076869
Drug: Comparator: lipid formulation of amphotericin B and/or azole
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01714856
Drug: Ropinirole hydrochloride CR 2mg Tablets
RxNorm normalized name: Ropinirole Hydrochloride
DrugBank: Ropinirole (DB00268)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ropinirole is an orally administered non-ergoline dopamine agonist. Ropinirole is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease.
Trial: NCT03681184
Drug: Lumasiran
RxNorm normalized name: lumasiran
DrugBank: Lumasiran (DB15935)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Lumasiran by SC injection
Trial: NCT01304303
Drug: SPARC1023 I
RxNorm normalized name: I 123
DrugBank: Iodide I-123 (DB09420)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV administration
Trial: NCT02651688
Drug: Enclomiphene
RxNorm normalized name: Enclomiphene
DrugBank: Enclomiphene (DB06735)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enclomiphene capsule daily in the morning with approximately 8 ounces of water for up to 12 months.
Trial: NCT02509793
Drug: Tetrabenazine
RxNorm normalized name: Tetrabenazine
DrugBank: Tetrabenazine (DB04844)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Xenazine, pill, dose to effect, three times a day, for 12 weeks
Trial: NCT00839787
Drug: Morphine Sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine Sulfate group: If weight is \<50 Kg; Morphine 0.1mg/kg IV to a maximum of 10mg can be given; if weight ≥ 50 Kg a maximum of 10mg can be given
Trial: NCT00006378
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00006378
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00441987
Drug: GSI-953
RxNorm normalized name: GSI-136
DrugBank: GSI-136 (DB12819)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00456261
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: pemetrexed 500 mg/m2
Trial: NCT00456261
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: gemcitabine 1500 mg/m2
Trial: NCT00456261
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: bevacizumab 10mg/kg bevacizumab 15mg/kg
Trial: NCT00456261
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: carboplatin AUC=5
Trial: NCT00396383
Drug: plerixafor
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants were given a 240 µg/kg dose of plerixafor by subcutaneous injection in the morning followed by apheresis 6 hours later. Daily treatment with plerixafor followed by apheresis was administered for up to 4 consecutive days or until 4\*10\^6 CD34+ cells/kg body weight had been collected.
Trial: NCT00103298
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00103298
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01648192
Drug: Losmapimod for single dose
RxNorm normalized name: Losmapimod
DrugBank: Losmapimod (DB12270)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film coated white tablet
Trial: NCT01648192
Drug: Losmapimod for repeat dose
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
DrugBank: Losmapimod (DB12270)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film coated white tablet
Trial: NCT02703376
Drug: Oral Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intakes of Oral Prednisone for 12 weeks after balloon dilations
Trial: NCT02156063
Drug: NT100
RxNorm normalized name: POMEGRANATE 250 mg / EUCOMMIA ULMOIDES BARK 200 mg / ACHYRANTHES JAPONICA ROOT 50 mg ORAL TABLET [HL Joint100 for Joint and Cartilage]
DrugBank: Eucommia ulmoides bark (DB14259)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00944307
Drug: raltegravir
RxNorm normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: raltegravir 400mg orally once
Trial: NCT00944307
Drug: antacid
RxNorm normalized name: Antacid
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: aluminum, magnesium, simethicone-containing antacid 30mL orally once
Trial: NCT02003456
Drug: Cardiac PET scan w/18F-Fluorodeoxyglucose and rubidium-82
DrugBank: Rubidium (DB11346)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study subjects will undergo a Cardiac PET scan that will take approximately 20 minutes to complete. In addition to standard clinical rubidium-82/18F-fluorodeoxyglucose (FDG) PET imaging, during a separate imaging session, participants will be infused with a second dose of the radio-tracer rubidium-82 during FDG imaging scan that will take an additional 10 to 15 minutes to complete.
Trial: NCT03731026
Drug: 68Ga-RM2
RxNorm normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiopharmaceutical: 68Ga-RM2 is an investigational Positron Emission Tomography (PET)/ Computed Tomography (CT) radiopharmaceutical.
Trial: NCT01558713
Drug: Bupivacaine- Fentanyl - Normal Saline
RxNorm normalized name: BUPIVACAINE/FENTANYL
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus
Trial: NCT01558713
Drug: Ropivacaine-Fentanyl-Normal Saline
RxNorm normalized name: fentanyl / ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0,75%, 2ml (15mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus
Trial: NCT01558713
Drug: Levobupivacaine- Fentanyl- Normal Saline
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levo-bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus
Trial: NCT01558713
Drug: Bupivacaine + Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus
Trial: NCT01558713
Drug: Ropivacaine + Fentanyl
RxNorm normalized name: fentanyl / ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0,75%, 2ml (15mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus.
Trial: NCT01558713
Drug: Levobupivacaine + Fentanyl
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levo-bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus
Trial: NCT02295787
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal ketamine for late-life depression and suicidal ideation.
Trial: NCT00006110
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 90 mg/m2 weekly, intravenously 1 hour after herceptin, given weekly up to 12 weeks or 175 mg/m2, intravenously every 3 weeks, up to 12 weeks (only if not receiving Herceptin®)
Trial: NCT00617513
Drug: Prucalopride
RxNorm normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 0.5 mg once daily
Trial: NCT00617513
Drug: Prucalopride
RxNorm normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1 mg o.d.
Trial: NCT00617513
Drug: Prucalopride
RxNorm normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 2 mg o.d.
Trial: NCT01037816
Drug: FS-67 Patch
RxNorm normalized name: factor VIII
DrugBank: Antihemophilic factor, human recombinant (DB00025)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One FS-67 patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
Trial: NCT01538537
Drug: rigosertib sodium
RxNorm normalized name: Rigosertib
DrugBank: Rigosertib (DB12146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ON 01910.Na will be supplied as a sterile, concentrated solution (75 mg/ml) in labeled, sealed glass vials. ON 01910.Na concentrated solution (75 mg/ml) must be diluted before intravenous administration. The starting dose will be 50 mg/m2 over 24 hour infusion daily for 3 days. A fresh infusion must be prepared for each day of the 3-day continuous infusion. This 3-day continuous treatment followed by 11 days without administration of study drug will constitute 1 Cycle. Cycles can be repeated every 2 weeks. The dosing of ON 01910.Na will be based on body surface area (BSA). In the absence of toxicity that would cause accelerated dose escalation to cease, drug doses are planned to escalate every 3 weeks.
Trial: NCT02069093
Drug: Dexamethasone based mouthwash
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone steroid-based oral solution, comprised of 0.5 milligrams per 5mL of alcohol-free dexamethasone.
Trial: NCT02069093
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Commercially available everolimus 10 mg was prescribed to participants by the Investigator according to local regulations.
Trial: NCT02069093
Drug: Exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available exemestane 25 mg was prescribed to participants by the Investigator according to local regulations.
Trial: NCT00629148
Drug: Vinorelbine and Capecitabine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinorelbine 25mg/m2 D1, D8 q3w Capecitabine 1000mg/m2 D1-D14 q3w
Trial: NCT00629148
Drug: Vinorelbine and Capecitabine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinorelbine 25mg/m2 D1, D8 q3w. When disease progression or untolerated toxicity occurs, Capecitabine 1000mg/m2 D1-D14 q3w
Trial: NCT00594217
Drug: oral micronized progesterone suspension
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral micronized progesterone suspension, single 100 mg oral dose
Trial: NCT02897063
Drug: Droxidopa
RxNorm normalized name: Droxidopa
DrugBank: Droxidopa (DB06262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single oral dose 300 mg
Trial: NCT02897063
Drug: Midodrine
RxNorm normalized name: Midodrine
DrugBank: Midodrine (DB00211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single oral dose 10 mg
Trial: NCT01603394
Drug: pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin Capsules (150 mg - 600mg), Dose titration (4 weeks) and fixed dose (2 weeks) for a 6 week treatment period.
Trial: NCT05765357
Drug: Herceptin
RxNorm normalized name: Herceptin
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Herceptin is the brand name of Trastuzumab for injection manufactured by Roche. Trastuzumab is a humanized IGG1-class monoclonal antibody produced by CHO cells. Its mechanism of action is to prevent the attachment of human epidermal growth factor to Her2 by attaching itself to Her2, thus blocking the growth of cancer cells. In addition, Trastuzumab can also stimulate the body's own immune cells to destroy cancer cells.
Trial: NCT03609190
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: i.v. infusion of 0.25 mg/kg S-ketamine over 40 min
Trial: NCT03602833
Drug: Compound 451238
RxNorm normalized name: Blackburn Compound
DrugBank: Drostanolone propionate (DB14655)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each patient will receive compound 451238 until disease progression unacceptable toxicities.
Trial: NCT00431145
Drug: Niacin
RxNorm normalized name: Niacin
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00431145
Drug: Niacin+Statin
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01433419
Drug: TAK-875
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01403259
Drug: S-1 plus oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: S-1 60 mg BID at day 1-14 Oxaliplatin 100 mg/m2 at day 1 Frequence of cycles: every 3 weeks